Literature DB >> 21341973

Isolation and expansion of oligodendrocyte progenitor cells from cryopreserved human umbilical cord blood.

Elisabeth T Tracy1, Claire Y Zhang, Tracy Gentry, Kevin W Shoulars, Joanne Kurtzberg.   

Abstract

BACKGROUND AIMS: Oligodendrocyte precursor cells (OPC) hold promise as a cellular therapy for demyelinating diseases. The feasibility of using OPC-based therapies in humans depends upon a reliable, readily available source. We have previously described the isolation, expansion and characterization of oligodendrocyte-like cells from fresh human umbilical cord blood (UCB). We now describe the isolation and expansion of OPC from thawed, cryopreserved UCB.
METHODS: We thawed cryopreserved UCB units employing a standard clinical protocol, then isolated and plated mononuclear cells under previously established culture conditions. All OPC cultures were trypsinized at 21 days, counted, then characterized by flow cytometry after fixation, permeablization and labeling with the following antibodies: anti-oligodendrocyte marker 4 (O4), anti-oligodendrocyte marker 1 (O1) and anti-myelin basic protein (MBP). OPC were also placed in co-culture with shiverer mouse neuronal cells then stained in situ for beta tubulin III (BT3) and MBP as a functional assay of myelination.
RESULTS: The average OPC yield per cryopreserved UCB unit was 64% of that seen with fresh UCB. On flow cytometric analysis, 74% of thawed UCB units yielded cells with an O4-expression level of at least 20% of total events, compared with 95% of fresh UCB units. We observed myelination of shiverer neurons in our functional assay, which could be used as a potency assay for release of OPC cells in phase I human clinical trials.
CONCLUSIONS: Our results demonstrate that OPC can be derived reliably from thawed, cryopreserved UCB units, and support the feasibility of using these cells in human clinical trials.

Entities:  

Mesh:

Year:  2011        PMID: 21341973      PMCID: PMC3152318          DOI: 10.3109/14653249.2011.553592

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  24 in total

Review 1.  Neural stem cells: an overview.

Authors:  Rossella Galli; Angela Gritti; Luca Bonfanti; Angelo Luigi Vescovi
Journal:  Circ Res       Date:  2003-04-04       Impact factor: 17.367

2.  Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.

Authors:  Maria L Escolar; Michele D Poe; James M Provenzale; Karen C Richards; June Allison; Susan Wood; David A Wenger; Daniel Pietryga; Donna Wall; Martin Champagne; Richard Morse; William Krivit; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

3.  Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation.

Authors:  S Liu; Y Qu; T J Stewart; M J Howard; S Chakrabortty; T F Holekamp; J W McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 4.  Stem cells for the treatment of myelin loss.

Authors:  Hans S Keirstead
Journal:  Trends Neurosci       Date:  2005-10-05       Impact factor: 13.837

5.  Embryonic stem cell-derived glial precursors: a source of myelinating transplants.

Authors:  O Brüstle; K N Jones; R D Learish; K Karram; K Choudhary; O D Wiestler; I D Duncan; R D McKay
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

6.  Rapid preimplantation detection of mutant (shiverer) and normal alleles of the mouse myelin basic protein gene allowing selective implantation and birth of live young.

Authors:  C M Gomez; A L Muggleton-Harris; D G Whittingham; L E Hood; C Readhead
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation.

Authors:  Gabriel I Nistor; Minodora O Totoiu; Nadia Haque; Melissa K Carpenter; Hans S Keirstead
Journal:  Glia       Date:  2005-02       Impact factor: 7.452

8.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.

Authors:  P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  The myelin basic protein gene is expressed in differentiated blood cell lineages and in hemopoietic progenitors.

Authors:  M C Marty; F Alliot; J Rutin; R Fritz; D Trisler; B Pessac
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

10.  Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy.

Authors:  Maria I Givogri; Francesca Galbiati; Stefania Fasano; Stefano Amadio; Laura Perani; Daniela Superchi; Pablo Morana; Ubaldo Del Carro; Sergio Marchesini; Riccardo Brambilla; Lawrence Wrabetz; Ernesto Bongarzone
Journal:  J Neurosci       Date:  2006-03-22       Impact factor: 6.167

View more
  8 in total

1.  Enhanced survival and neurite network formation of human umbilical cord blood neuronal progenitors in three-dimensional collagen constructs.

Authors:  Marian M Bercu; Hadar Arien-Zakay; Dana Stoler; Shimon Lecht; Peter I Lelkes; Simcha Samuel; Reuven Or; Arnon Nagler; Philip Lazarovici; Uriel Elchalal
Journal:  J Mol Neurosci       Date:  2012-12-12       Impact factor: 3.444

Review 2.  Models for Studying Myelination, Demyelination and Remyelination.

Authors:  I Osorio-Querejeta; M Sáenz-Cuesta; M Muñoz-Culla; D Otaegui
Journal:  Neuromolecular Med       Date:  2017-05-23       Impact factor: 3.843

3.  Human Umbilical Cord Blood Cells Ameliorate Motor Deficits in Rabbits in a Cerebral Palsy Model.

Authors:  Alexander Drobyshevsky; C Michael Cotten; Zhongjie Shi; Kehuan Luo; Rugang Jiang; Matthew Derrick; Elizabeth T Tracy; Tracy Gentry; Ronald N Goldberg; Joanne Kurtzberg; Sidhartha Tan
Journal:  Dev Neurosci       Date:  2015-03-17       Impact factor: 2.984

4.  Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases.

Authors:  Joanne Kurtzberg; Susan Buntz; Tracy Gentry; Pamela Noeldner; April Ozamiz; Benjamin Rusche; Robert W Storms; Amy Wollish; David A Wenger; Andrew E Balber
Journal:  Cytotherapy       Date:  2015-03-12       Impact factor: 5.414

5.  Bone marrow stromal cell transdifferentiation into oligodendrocyte-like cells using triiodothyronine as a inducer with expression of platelet-derived growth factor α as a maturity marker.

Authors:  Hojjat-Allah Abbaszadeh; Taki Tiraihi; Ali Reza Delshad; Majid Saghedi Zadeh; Taher Taheri
Journal:  Iran Biomed J       Date:  2013-04

Review 6.  Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.

Authors:  Jessica M Sun; Joanne Kurtzberg
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

Review 7.  Could cord blood cell therapy reduce preterm brain injury?

Authors:  Jingang Li; Courtney A McDonald; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Front Neurol       Date:  2014-10-09       Impact factor: 4.003

Review 8.  Cord-Blood-Derived Professional Antigen-Presenting Cells: Functions and Applications in Current and Prospective Cell Therapies.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.